• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Psyence Biomedical Ltd.

    9/5/25 4:05:13 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PBM alert in real time by email
    6-K 1 ea0255928-6k_psyence.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

    SECURITIES EXCHANGE ACT OF 1934

     

    For the month of September 2025

     

    Commission File Number: 001-41937

     

    Psyence Biomedical Ltd.

    (Translation of registrant’s name into English)

     

    121 Richmond Street West
    Penthouse Suite 1300
    Toronto, Ontario M5H 2K1 

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒       Form 40-F ☐

     

     

     

     

     

     

    Entry into Material Agreement

     

    On August 15, 2025, Psyence Biomedical Ltd. (the “Company”) entered into a subscription agreement (the “Agreement”) with Psyence Labs Ltd. (“PsyLabs”). Pursuant to the Agreement, PsyLabs agreed to issue to the Company 1,750 shares of PsyLabs at a price per share of $2,000, for an aggregate purchase price of $3,500,000. The closing of the transaction was conditioned upon the receipt of required approvals by the parties thereto. On September 1, 2025, the transaction closed.

     

    PsyLabs is a privately-held company specializing in the production of psychedelic active pharmaceutical ingredients and extracts for research, clinical trials, and drug development. The Company previously acquired a minority interest in PsyLabs, as disclosed in the Company’s annual report on Form 20-F. Certain executives, including the Executive Chairman, the Chief Financial Officer and the General Counsel, and an independent director, of the Company provide consulting services to PsyLabs in exchange for consulting fees. Such individuals, together with the Company’s Chief Executive Officer, own less than 5% of the outstanding shares of PsyLabs in the aggregate. Certain of these individuals are also members of the board of directors of a wholly-owned subsidiary of PsyLabs.

     

    1

     

     

    EXHIBIT INDEX

     

    Exhibit No.   Description
    99.1    Form of Subscription Agreement, dated August 15, 2025, by and between Psyence Biomedical Ltd. and Psyence Labs Ltd.

     

    2

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Dated: September 5, 2025

     

    Psyence Biomedical Ltd.  
         
    By: /s/ Jody Aufrichtig  
    Name: Jody Aufrichtig  
    Title: Executive Chairman  

     

     

    3

     

     

    Get the next $PBM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PBM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PBM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

    NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that it will present at the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8–10, 2025. The event, held at the Lotte New York Palace Hotel in New York City and virtually, features more than 550 corporate presentations from leading growth companies across healthcare, technology, and finance. Dr. Neil Maresky, CEO of Psyence BioMed, will provide an overview of the Company's business strategy and pipeline.

    8/28/25 8:00:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corporate Update, August 2025

    NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- From Dr. Neil Maresky, CEO, Psyence BioMed (NASDAQ:PBM) Dear Shareholders, Thank you for your continued support as we advance our mission to develop safe, effective, and naturally derived psychedelic therapies for people living with serious mental health challenges. Over the past few months, Psyence BioMed (PBM) has made meaningful progress across several fronts: clinical development, strategic positioning, regulatory compliance, and manufacturing stability. These developments reflect not only a shift in our momentum but also a broader evolution of the company – one I'm excited to share with you. Clinical Progress & Trial Expansion Psyence

    8/4/25 8:30:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production

    NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company") is pleased to announce that its strategic partner, PsyLabs – a leader in the production of purified psychedelic compounds – has successfully produced a GMP-aligned Ibogaine Total Alkaloid extract. The high-purity extract met all microbial safety standards for food-grade consumption, as verified by an accredited third-party laboratory. In 2024, Psyence BioMed acquired an equity stake in PsyLabs and continued that investment in 2025. This achievement reflects the impact of Psyence BioMed's ongoing investment and collaboration, which continues to support PsyLabs' development of

    7/31/25 7:30:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBM
    SEC Filings

    View All

    SEC Form 6-K filed by Psyence Biomedical Ltd.

    6-K - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

    9/5/25 4:05:13 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Psyence Biomedical Ltd.

    6-K - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

    8/28/25 4:05:03 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form F-3 filed by Psyence Biomedical Ltd.

    F-3 - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

    8/6/25 8:29:40 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBM
    Leadership Updates

    Live Leadership Updates

    View All

    Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board

    NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that it will work closely with Albert P. Garcia-Romeu, Ph.D., to chair and develop its newly created Scientific Advisory Board (SAB). Dr. Garcia-Romeu is a leading psychedelics researcher currently serving as Associate Professor in the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, as well as Associate Director, Johns Hopkins Center for Psychedelic and Consciousness Research and the Susan Hill Ward Professor in Psychedelics and Consciousness. He is a highly sought after speaker on the therapeutic potential of p

    2/26/25 8:00:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

    NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced the voting results for each of the matters presented at the Company's annual and special meeting of shareholders held on November 12, 2024 (the "Meeting"). Shareholders were represented in person or by proxy at the meeting holding 21,877,200 common shares, representing approximately 43.5% of Psyence Biomed's 50,334,170 issued and outstanding common shares as of October 10, 2024, the record date for the Meeting. At the Meeting, a total of five resolutions (the "Resolutions" and each a "Resolution") were submitted to and approved by the Company's shareholder

    11/12/24 4:30:00 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant

    Clairvoyant currently executing a fully randomized multi-country Phase IIb clinical trial evaluating a synthetic psilocybin candidate as a potential therapeutic for Alcohol Use Disorder (AUD) Topline data from the ongoing Phase IIb AUD study anticipated in early 2025 NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that the Company has entered into a conditional binding term sheet with privately-held Clairvoyant Therapeutics Inc ("Clairvoyant"), a clinical-stage developer of psilocybin-based therapeutics based in Canada, for the proposed acquisition by Psyence Biomed of 100% of the shareholdings

    9/6/24 7:30:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Psyence Biomedical Ltd.

    SC 13G - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/13/24 9:16:01 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

    SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/9/24 1:36:43 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

    SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/4/24 4:38:27 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care